RhumbLine Advisers’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $52.7M | Buy |
312,832
+9,012
| +3% | +$1.34M | 0.04% | 371 |
|
|
2026
Q1 | $40M | Buy |
303,820
+6,376
| +2% | +$846K | 0.03% | 431 |
|
|
2025
Q4 | $42.2M | Sell |
297,444
-6,066
| -2% | -$879K | 0.03% | 420 |
|
|
2025
Q3 | $42.6M | Sell |
303,510
-5,680
| -2% | -$770K | 0.03% | 425 |
|
|
2025
Q2 | $38.9M | Sell |
309,190
-5,296
| -2% | -$607K | 0.03% | 445 |
|
|
2025
Q1 | $34.8M | Sell |
314,486
-5,992
| -2% | -$759K | 0.03% | 455 |
|
|
2024
Q4 | $43.7M | Sell |
320,478
-1,269
| -0.4% | -$157K | 0.04% | 374 |
|
|
2024
Q3 | $37.1M | Sell |
321,747
-2,541
| -0.8% | -$348K | 0.03% | 438 |
|
|
2024
Q2 | $44.6M | Buy |
324,288
+2,181
| +0.7% | +$299K | 0.04% | 360 |
|
|
2024
Q1 | $44.4M | Buy |
322,107
+3,187
| +1% | +$435K | 0.04% | 362 |
|
|
2023
Q4 | $42M | Sell |
318,920
-6,593
| -2% | -$759K | 0.04% | 354 |
|
|
2023
Q3 | $36.6M | Sell |
325,513
-2,794
| -0.9% | -$294K | 0.04% | 365 |
|
|
2023
Q2 | $31M | Buy |
328,307
+21,713
| +7% | +$2.12M | 0.03% | 440 |
|
|
2023
Q1 | $31M | Buy |
306,594
+6,596
| +2% | +$686K | 0.04% | 423 |
|
|
2022
Q4 | $35.8M | Buy |
299,998
+12,548
| +4% | +$1.47M | 0.05% | 357 |
|
|
2022
Q3 | $30.5M | Buy |
287,450
+9,015
| +3% | +$915K | 0.05% | 372 |
|
|
2022
Q2 | $27.1M | Buy |
278,435
+23,171
| +9% | +$2.14M | 0.04% | 407 |
|
|
2022
Q1 | $23.9M | Buy |
255,264
+364
| +0.1% | +$30.8K | 0.03% | 499 |
|
|
2021
Q4 | $21.7M | Buy |
254,900
+3,837
| +2% | +$353K | 0.03% | 575 |
|
|
2021
Q3 | $24.1M | Sell |
251,063
-926
| -0.4% | -$87.5K | 0.03% | 489 |
|
|
2021
Q2 | $24.5M | Sell |
251,989
-2,172
| -0.9% | -$208K | 0.03% | 505 |
|
|
2021
Q1 | $24.7M | Buy |
254,161
+140,532
| +124% | +$14.7M | 0.03% | 490 |
|
|
2020
Q4 | $10.9M | Sell |
113,629
-6,300
| -5% | -$608K | 0.02% | 862 |
|
|
2020
Q3 | $11.5M | Sell |
119,929
-7,852
| -6% | -$908K | 0.02% | 696 |
|
|
2020
Q2 | $15.6M | Buy |
127,781
+27,323
| +27% | +$3.02M | 0.03% | 553 |
|
|
2020
Q1 | $8.7M | Buy |
100,458
+99
| +0.1% | +$9.69K | 0.02% | 716 |
|
|
2019
Q4 | $10.8M | Buy |
100,359
+2,649
| +3% | +$277K | 0.02% | 793 |
|
|
2019
Q3 | $8.8M | Sell |
97,710
-431
| -0.4% | -$40.3K | 0.02% | 839 |
|
|
2019
Q2 | $8.29M | Buy |
98,141
+600
| +0.6% | +$49.3K | 0.02% | 885 |
|
|
2019
Q1 | $8.59M | Buy |
97,541
+204
| +0.2% | +$17.1K | 0.02% | 846 |
|
|
2018
Q4 | $6.95M | Sell |
97,337
-4,316
| -4% | -$413K | 0.02% | 902 |
|
|
2018
Q3 | $12.5M | Sell |
101,653
-2,017
| -2% | -$229K | 0.02% | 588 |
|
|
2018
Q2 | $10.2M | Buy |
103,670
+1,915
| +2% | +$171K | 0.02% | 675 |
|
|
2018
Q1 | $8.44M | Sell |
101,755
-3,067
| -3% | -$259K | 0.02% | 735 |
|
|
2017
Q4 | $8.13M | Sell |
104,822
-739
| -0.7% | -$50.4K | 0.02% | 796 |
|
|
2017
Q3 | $6.47M | Sell |
105,561
-2,433
| -2% | -$128K | 0.01% | 888 |
|
|
2017
Q2 | $4.97M | Sell |
107,994
-1,860
| -2% | -$90.2K | 0.01% | 1005 |
|
|
2017
Q1 | $4.76M | Buy |
109,854
+2,634
| +2% | +$113K | 0.01% | 1033 |
|
|
2016
Q4 | $4.15M | Buy |
107,220
+7,681
| +8% | +$348K | 0.01% | 1033 |
|
|
2016
Q3 | $5.04M | Buy |
99,539
+6,556
| +7% | +$327K | 0.01% | 879 |
|
|
2016
Q2 | $4.23M | Sell |
92,983
-6,344
| -6% | -$292K | 0.01% | 905 |
|
|
2016
Q1 | $3.93M | Buy |
99,327
+1,975
| +2% | +$78.4K | 0.01% | 973 |
|
|
2015
Q4 | $5.51M | Buy |
97,352
+6,835
| +8% | +$347K | 0.02% | 774 |
|
|
2015
Q3 | $3.6M | Buy |
90,517
+3,112
| +4% | +$150K | 0.01% | 978 |
|
|
2015
Q2 | $4.17M | Sell |
87,405
-1,265
| -1% | -$53.6K | 0.01% | 948 |
|
|
2015
Q1 | $3.52M | Buy |
88,670
+20,330
| +30% | +$727K | 0.01% | 1046 |
|
|
2014
Q4 | $1.53M | Sell |
68,340
-3,710
| -5% | -$70.3K | ﹤0.01% | 1534 |
|
|
2014
Q3 | $1.13M | Buy |
72,050
+1,330
| +2% | +$19.9K | ﹤0.01% | 1681 |
|
|
2014
Q2 | $1.05M | Buy |
70,720
+3,860
| +6% | +$54.5K | ﹤0.01% | 1787 |
|
|
2014
Q1 | $1.08M | Sell |
66,860
-3,200
| -5% | -$54.7K | ﹤0.01% | 1753 |
|
|
2013
Q4 | $654K | Sell |
70,060
-100
| -0.1% | -$976 | ﹤0.01% | 2091 |
|
|
2013
Q3 | $794K | Sell |
70,160
-612
| -0.9% | -$8.41K | ﹤0.01% | 1929 |
|
|
2013
Q2 | $947K | Buy |
+70,772
| New | +$869K | ﹤0.01% | 1791 |
|
Other funds holding NBIX
VPM
VCM
RhumbLine Advisers's NBIX Position: Q2 2026 in Review
RhumbLine Advisers increased its Neurocrine Biosciences (NBIX) stake by 3% in Q2 2026, buying an estimated $1.34M and bringing the position to 312,832 shares worth $52.7M. The position accounts for 0.04% of the portfolio, ranked #371.
RhumbLine Advisers first reported a position in NBIX in Q2 2013 and has held it in 53 quarters since. 696 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- RhumbLine Advisers held 312,832 shares of Neurocrine Biosciences worth $52.7M as of Q2 2026.
- RhumbLine Advisers bought 9,012 Neurocrine Biosciences shares in Q2 2026, an estimated $1.34M.
- Neurocrine Biosciences made up 0.04% of RhumbLine Advisers's portfolio in Q2 2026, its #371 holding.
- RhumbLine Advisers first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 53 quarters since.
- 696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.